Answers are grounded in this paper and cite their sources.
Integrating photochemical catalyst activation and stereochemical control within a single catalyst architecture offers an attractive strategy for asymmetric synthesis. Herein, we report a chiral photoactive nickel catalyst that enables enantioconvergent light-mediated C(sp 2 )–C(sp 3 ) crosscoupling of an N-Boc-protected pyrrolidine-derived trifluoroborate with (hetero)aryl bromides. The catalyst features a carbazole-decorated biimidazole (biIm) ligand that combines intraligand chargetransfer (ILCT) photoactivity with asymmetric induction, thereby eliminating the need for a separate photocatalyst. The optimized system affords enantioenriched products with high enantioselectivity across a broad range of aryl bromides. Mechanistic investigations provide evidence for stereochemical scrambling through reversible Ni–C bond homolysis, offering a possible pathway for enantioconvergence. These findings establish chiral photoactive ligands as a platform for integrating light-driven catalyst activation and asymmetric cross-coupling catalysis.
No takes yet. Share an insight, caveat, or question.
Giannoudis et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: